Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Venetoclax

A BH3-mimetic cancer medicine that blocks BCL-2, a protein that keeps leukaemia cells alive, pushing them towards programmed cell death: approved in 2016 in the United States and Europe, it is used for chronic lymphocytic leukaemia and acute myeloid leukaemia. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.

Did you know?It was the first approved medicine that works by blocking an interaction between proteins: it mimics the BH3 proteins, which normally bind to BCL-2 to start the cell's self-destruction.

VenetoclaxGo to the active ingredient →
VenetoclaxActive ingredientVenetoclaxCat. No. P-V027-001CAS 1257044-40-8
Venetoclax-d8Isotopically labelledVenetoclax-d8Cat. No. P-V027-003CAS 1257051-06-1

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.